Fas Antigen/APO-1 (CD95) Expression on Myeloma Cells

References

• Yoshizaki K., Nakagawa T., Kaieda T., Muraguchi A., Yamamura Y., Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J. Immunol. 1982; 128: 1296–301
   PubMed Web of Science ®Google Scholar
• Splauski J. B., McAnally L. M., Lipsky P. E. IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J. Immunol. 1990; 144: 562–9
   PubMed Web of Science ®Google Scholar
• Xia X., Lee H. L., Clark S. C., Choi Y. S. Recombinant interleukin (IL)2-induced human B cell differentiation is mediated by autocrine IL6. Eur. J. Immunol. 1989; 19: 2275–81
   PubMed Web of Science ®Google Scholar
• Hirano T., Taga T., Nakano N., Yasukawa K., Kashiwamura S., Shimizu K., Nakajima K., Pyun K. H., Kishimoto T. Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSF-2). Proc. Natl. Acad. Sci. USA 1985; 82: 5490–4
   PubMed Web of Science ®Google Scholar
• Muraguchi A., Hirano T., Tang B., Matsuda T., Hori Y., Nakajima K., Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 1988; 167: 332–44
   PubMed Web of Science ®Google Scholar
• Raynal M. C., Liu Z., Hirano T., Mayer L., Kishimoto T., Chen-Kiang S. Interleukin 6 induces secretion of IgGl by coordinated transcriptional activation and differential mRNA accumulation. Proc. Natl. Acad. Sci. USA 1989; 86: 8024–8
   PubMed Web of Science ®Google Scholar
• Tanner J. E., Tosato G. Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 1992; 79: 452–9
   PubMed Web of Science ®Google Scholar
• May L. T., Ghrayeb J., Santhanem U., Tatter S. B., Sthoeger Z., Helfgott D. C., Chiorazzi N., Grieninger G., Sehgal P. B. Synthesis and secretion of multiple forms of β2-interferon B-cell differentiation factor-2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J. Biol. Chem. 1988; 263: 7760–66
   PubMed Web of Science ®Google Scholar
• Sironi M., Breviario F., Proserpio P., Biondi A., Vecchi A., Van Damme J., Dejana E., Montovani A. IL-1 stimulates IL-6 production in endothelial cells. J. Immunol. 1989; 142: 549–53
   PubMed Web of Science ®Google Scholar
• Grossman A., Krueger R., Yourish J., Granelli-Piperno A., Murphy D. P., May L. T., Kupper T. S., Sehgal P. B., Gottlieb A. B. Interleukin 6 is expressed in high levels in psoriasis skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 1989; 86: 6367–71
   PubMed Web of Science ®Google Scholar
• Horii Y., Muraguchi A., Iwano M., Matsuda T., Hirayama T., Yamada H., Fujii Y., Dohi K., Ishikawa H., Ohmoto Y., Yoshizaki K., Hirano T., Kishimoto T. Involvement of interleukin-6 in mesangial proliferative glomerulonephritis. J. Immunol. 1989; 143: 3949–55
   PubMed Web of Science ®Google Scholar
• Hamid Q., Barkans J., Meng Q., Ying S., Abrams J. S., Kay A. B., Moqbel R. Human eosinophils synthesize and secrete interleukin-6. in vitro. Blood 1992; 80, 1496–501
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–5
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X-G., Jourdan M., Content J., Houssiau F., Anden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors'. Blood 1989; 73: 1915–24
   PubMed Web of Science ®Google Scholar
• Zhang X-G., Gu J-J., Lu Z-Y., Yasukawa K., Yanocopoulos G. D., Turner K., Shoyab M., Taga T., Kishimoto T., Bataille R., Klein B. Ciliary neutropic factor, interleukin II, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med. 1994; 177: 1337–42
   Web of Science ®Google Scholar
• Nishimoto N., Ogata A., Shima Y., Tani Y., Ogawa H., Nakagawa M., Sugiyama H., Yoshizaki K., Kishimoto T. Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J. Exp. Med. 1994; 177: 1343–47
   Web of Science ®Google Scholar
• Hermann F., Andreef M., Gruss H. J., Brach M. A., LÜBbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 1991; 78: 2070–74
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Schoester M., De Leeuw K. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Br. J. Haematol. 1991; 79: 589–94
   PubMed Web of Science ®Google Scholar
• Zhang X-G., Bataille R., Widjenes J., Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992; 69: 1373–76
   PubMed Web of Science ®Google Scholar
• Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. 1989; 170: 613–8
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannori P. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cell. Blood 1990; 76: 2599–605
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Tribalto M. Biology and treatment of multiple myeloma. Curr. Opn. Oncol. 1992; 4: 73–86
   PubMedGoogle Scholar
• Shima Y., Nishimoto N., Ogata A., Fujii Y., Yoshizaki K., Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757–64
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor-A paradigm for cytokines. Science 1992; 258: 593–7
   PubMed Web of Science ®Google Scholar
• Yasukawa K., Futatsugi K., Saito T., Yawata H., Harazaki M., Suzuki H., Taga T., Kishimoto T. Association of recombinant soluble IL-6-signal transducer gp130 with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol. lett. 1992; 31: 123–30
   PubMed Web of Science ®Google Scholar
• Ip N. Y., Nye S. H., Boulton T. G., Davis S., Taga T., Li Y., Yasukawa K., Kishimoto T., Anderson D. J., Stahl N., Yancopoulous G. D. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 1992; 69: 1121–32
   PubMed Web of Science ®Google Scholar
• Gearing D. P., Comeau M. R., Friend D. J., Gimpel S. D., Thul C. J., McGourty J., Brasher K. K., King J. A., Gillis S., Mosley B., Ziegler S. F., Cosman D. The IL-6 signal transducer gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255: 1434–7
   PubMed Web of Science ®Google Scholar
• Portier M., Zhang X-G., Caron E., Lu Z-Y., Bataille R., Klein B. γ-interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6 receptor expression in vitro. Blood 1993; 81: 3076–82
   PubMed Web of Science ®Google Scholar
• Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989; 169: 1747–56
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–43
   PubMed Web of Science ®Google Scholar
• Oehm A., Behmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B. C., Ponstingl H., Krammer P. H. Purification and molecular cloning of the APO-l cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem. 1992; 267: 10709–15
   PubMed Web of Science ®Google Scholar
• Morimoto C. Activation antigens: section report. Leucocyte Typing V, S. F. Schlossman, L. Boumsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. F. Tedder, R. F. Todd. Oxford University Press, Oxford 1995; 1097–1104
   Google Scholar
• Kerr J. F. R. A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J. Path. Bact. 1965; 90: 419–35
   PubMedGoogle Scholar
• Biava C., Mukhlova-Montiel M. Electron microscopic observations on councilman-like acidophilic bodies and other forms of acidophilic changes in human liver cells. Am. J. Path. 1965; 46: 775–802
   PubMed Web of Science ®Google Scholar
• Kerr J. F. R. Lysosome changes in acute liver injury due to Heliotrine. J. Path. Bact. 1967; 93: 167–74
   PubMedGoogle Scholar
• Kerr J. R. F. An electron-microscope study of liver cell necrosis due to Heliotrine. J. Path. 1969; 97: 557–62
   PubMed Web of Science ®Google Scholar
• Kerr J. R. F., Wyllie A. H., Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972; 26: 239–57
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R., Brannan C. I., Copeland N. G. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–7
   PubMed Web of Science ®Google Scholar
• Nishimura Y., Ishii A., Kobayashi Y., Yamasaki Y., Yonehara S. Expression and function of mouse Fas antigen on immature and mature T cells. J. Immunol. 1995; 154: 4395–403
   PubMed Web of Science ®Google Scholar
• Yonehara S., Nishimura Y., Kishi S., Yonehara M., Takazawa K., Tamatani T., Ishii A. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int. Immunol. 1994; 6: 1849–56
   PubMed Web of Science ®Google Scholar
• King L. B., Ashwell J. D. Signaling for death of lymphoid cells. Current Opinion in Immunology 1993; 5: 368–73
   PubMed Web of Science ®Google Scholar
• Kappler J. W., Roehm N., Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273–80
   PubMed Web of Science ®Google Scholar
• Von Boehmer H. The developmental biology of T lymphocytes. Annu. Rev. Immunol. 1988; 6: 309–26
   PubMed Web of Science ®Google Scholar
• Cohen J. J. Programmed cell death in the immune system. Adv. Immunol. 1991; 50: 55–85
   PubMed Web of Science ®Google Scholar
• Kizaki H., Tadakuma T. Thymocyte apoptosis. Microbiol. Immunol. 1993; 37: 917–25
   PubMed Web of Science ®Google Scholar
• Siegel R. M., Katsumata M., Miyashita T., Louie D. C., Greene M. I., Reed J. C. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc. Natl. Acad. Sci. USA 1992; 89: 7003–7
   PubMed Web of Science ®Google Scholar
• Lawton A. R., Cooper M. D. Modification of B lymphocyte differentiation by anti-immunoglobulins. Contemp. Top. Immunol. 1974; 3: 193–225
   PubMedGoogle Scholar
• Nossal G. J. V. Cellular mechanisms of immunologic tolerance. Annu. Rev. Immunol. 1983; 1: 33–62
   PubMed Web of Science ®Google Scholar
• Goodnow C. C., Crosbie J., Adelstein S., Lavoie T. B., Smith-Gill S. J., Brink R. A., Pritchard-Briscoe H., Wotherspoon J. S., Loblay R. H., Raphael K., Trent R. J., Basten A. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334: 676–82
   PubMed Web of Science ®Google Scholar
• Nemazee D., Buerki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC-class I antibody genes. Nature 1989; 337: 562–6
   PubMed Web of Science ®Google Scholar
• Hasbold J., Klaus G. G. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur. J. Immunol. 1990; 20: 1685–90
   PubMed Web of Science ®Google Scholar
• Murakami M., Tsubata T., Okamoto M., Shimizu A., Kumagai S., Imura H., Honjo T. Antigen-induced apoptotic death of Ly-IB cells responsible for autoimmune diesase in transgenic mice. Nature 1992; 357: 77–80
   PubMed Web of Science ®Google Scholar
• Okamoto M., Murakami M., Shimizu A., Ozaki S., Tsubata T., Kumagai S., Honjo T. A transgenic model of autoimmune hemolytic anemia. J. Exp. Med. 1992; 175: 71–9
   PubMed Web of Science ®Google Scholar
• Russell D. M., Dembic Z., Morahan G., Miller J. F. A. P., BÜRki K., Nemazee D. Peripheral deletion of self-reactive B cells. Nature 1991; 354: 308–11
   PubMed Web of Science ®Google Scholar
• MÖLler P., Henne C., LeithÄUser F., Eichelmann A., Schmidt A., BrÜDerlein S., Dhein J., Krammer P. H. Coregulation of the APO-1 antigen with intercellular adhension molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 1993; 81: 2067–75
   PubMed Web of Science ®Google Scholar
• Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Cell Biology 1991; 88: 6961–5
   Google Scholar
• Tsujimoto Y., Cossman J., Jaffe E. Involvement of bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440–3
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879–86
   PubMed Web of Science ®Google Scholar
• Henderson S., Huen D., Rowe M., Dawson C., Johnson G., Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 1993; 90: 8479–83
   PubMed Web of Science ®Google Scholar
• Hockenbery D., NuÑEz G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–6
   PubMed Web of Science ®Google Scholar
• Tsubata T., Wu J., Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by T-cell signal through CD40. Nature 1993; 364: 645–8
   PubMed Web of Science ®Google Scholar
• Johnson P. W., Watt S. M., Betts D. R., Davies D., Jordan S., Norton A. J., Lister T. A. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 15: 1848–57
   Google Scholar
• Mapara M. Y., Bargou R., Zugck C., DÖHner H., Ustaoglu F., Jonker R. R., Krammer P. H., DÖRken B. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol. 1993; 23: 702–8
   PubMed Web of Science ®Google Scholar
• Trauth B. C., Klas C., Peters A. M. J., Matzku S., MÖLler P., Falk W., Debatin K-M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–5
   PubMed Web of Science ®Google Scholar
• Westendorf J. J., Lammert J. M., Jelinek D. F. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85: 3566–76
   PubMed Web of Science ®Google Scholar
• Kawano M. M., Huang N., Harada H., Harada Y., Sakai A., Tanaka H., Iwato K., Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–70
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Raymond N. M., Kyle R. A., O'Fallon W. M. Multiple myeloma: significance of plasma-Mastic subtype in morphological classification. Blood 1985; 65: 305–10
   PubMed Web of Science ®Google Scholar
• Boise L. H., GonzÁLez-GarcÍA M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., NuÑEz G., Thompson C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–19
   PubMed Web of Science ®Google Scholar
• Sulston J. E., Horivitz H. R. Post-embryonic cell lineages of the nematode Caenorhabditis elegans. Dev. Biol. 1977; 82: 110–56
   Web of Science ®Google Scholar
• Sulston J. E., Schierenberg E., White J. G., Thomson N. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev. Biol. 1983; 100: 64–119
   PubMed Web of Science ®Google Scholar
• Hedgecock E., Sulston J. E., Thomson N. Mutations affecting programmed cell death in the nematode Caenorhabditis elegans. Science 1983; 220: 1277–80
   PubMed Web of Science ®Google Scholar
• Ellis H. M., Horvitz H. R. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817–29
   PubMed Web of Science ®Google Scholar
• Ellis R. E., Horvitz H. R. Two C. elegans genes control the programmed deaths of specific cells in the pharynx. Development 1991; 112: 591–603
   PubMed Web of Science ®Google Scholar
• Ellis R. E., Jacobson D., Horvitz H. R. Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans. Genetics 1991; 129: 79–94
   PubMed Web of Science ®Google Scholar
• Cerretti D. P., Kozlosky C. J., Mosley B., Nelson N., Ness K. V., Greenstreet T. A., March C. J., Kronheim S. R., Druck T., Cannizzaro L. A., Huebner K., Black R. A. Molecular cloning of the interleukin-1β converting enzyme. Science 1992; 256: 97–100
   PubMed Web of Science ®Google Scholar
• Yuan J., Shaham S., Ledoux S., Ellis H. M., Horvitz H. R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993; 75: 641–52
   PubMed Web of Science ®Google Scholar
• Miura M., Zhu H., Rotello R., Hartwieg E. A., Yuan J. Induction of apoptosis in fibroblasts by IL-1b-converting enzyme, a mammalian homology of the C. elegans cell death gene ced-3. Cell 1993; 75: 653–60
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K., Tanaka H., Asaoku H., Tanabe O., Ishikawa H., Nobuyoshi M., Ohmoto Y., Hirai Y., Kuramoto A. Interleukin-1 beta rather than lympho-toxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73: 1646–9
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A. R., Lansdorp P. M., Di-Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–7
   PubMed Web of Science ®Google Scholar
• Lichtenstein A., Berenson J., Noeman D., Chang M. P., Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74: 1266–73
   PubMed Web of Science ®Google Scholar
• Yamamoto I., Kawano M., Sone T., Iwato K., Tanaka H., Ishikawa H., Kitamura N., Lee K., Shigeno C., Konishi J., Asaoku H., Tanabe O., Nobuyoshi M., Ohmoto Y., Hirai Y., Higuchi M., Ohsawa T., Kuramoto A. Production of interleukin 1 beta, a potent bone resorting cytokine, by cultured human myeloma cells. Cancer Res. 1989; 49: 4242–6
   PubMed Web of Science ®Google Scholar
• Teshigawara K., Maeda M., Nishino K., Nikaido T., Uchiyama T., Tsudo M., Wano Y., Yodoi J. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J. Mol. Cell. Immunol. 1985; 2: 17–26
   PubMedGoogle Scholar
• Okada M., Maeda M., Tagaya Y., Taniguchi Y., Teshigawara K., Yoshiki T., Diamantstein T., Smith K. A., Uchiyama T., Honjo T., Yodoi J. TCGF(IL2)-receptor inducing factor(s), possible role of ATL-derived factor (ADF) on constitutive IL 2 receptor expression of HTLV-I(+) T cell lines. J. Immunol. 1985; 135: 3995–4003
   PubMed Web of Science ®Google Scholar
• Holmgren A. Thioredoxin. Annu. Rev. Biochem. 1985; 54: 237–71
   PubMed Web of Science ®Google Scholar
• Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., Brown N., Arai K., Yokota T., Wakasugi H., Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologuous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 1989; 8: 757–64
   PubMed Web of Science ®Google Scholar
• Tagaya Y., Wakasugi H., Masutani H., Nakamura H., Iwata S., Mitsui A., Fujii S., Wakasugi N., Tursz T., Yodoi J. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction. Mol. Immunol. 1990; 27: 1279–89
   PubMed Web of Science ®Google Scholar
• Matsuda M., Masutani H., Nakamura H., Miyajima S., Yamauchi A., Yonehara S., Uchida A., Irimajiri K., Horiuchi A., Yodoi J. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol. 1991; 147: 3837–41
   PubMed Web of Science ®Google Scholar
• Okamoto T., Ogiwara H., Hayashi T., Mitsui A., Kawabe T., Yodoi J. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol. 1992; 4: 811–9
   PubMed Web of Science ®Google Scholar
• Yodoi J., Uchiyama T. Diseases associated with HTLV-1: virus, IL-2 receptor dysregulation and redox regulation. Immunol. Today 1992; 13: 405–11
   PubMedGoogle Scholar
• Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz M. D. Protection from Fasmediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–62
   PubMed Web of Science ®Google Scholar